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1 Analogues of adenine nucleotides inhibited /-adrenoceptor-stimulated cyclic AMP accumulation in
C6 rat glioma cells with a pharmacological selectivity consistent with that for involvement of a P2y-
purinoceptor.
2 The inhibitory effect of adenine nucleotides was completely prevented by pretreatment of cells with
pertussis toxin.
3 The capacity of a series of recently synthesized 2-thioether analogues of adenine nucleotides to inhibit
cyclic AMP accumulation was examined. Several ATP analogues, e.g. 2-cyclohexylthio and 2-hexylthio
ATP, inhibited cyclic AMP accumulation with EC50 values of approximately 30 pM. These values
represent 100,000 fold increases in potency over ATP.
4 Analogues of ADP exhibited the same remarkable increase in potency relative to their natural
congener and diphosphates were at least as potent as the corresponding triphosphates at the C6 cell P2y-
purinoceptor.
5 The relative potencies of a broad series of agonists at the C6 cell receptor did not correspond to the
relative potencies of the same compounds for activation of P2Y-purinoceptors on turkey erythrocyte
membranes. Some agonists, particularly 2-thioether derivatives were more potent for stimulation of the
C6 cell receptor, whereas other agonists were more potent in the turkey erythrocyte system.
6 These results add further support to the view that the adenylyl cyclase-linked P2y-purinoceptor of C6
rat glioma cells is a different subtype from the phospholipase C-linked P2y-purinoceptor of turkey
erythrocyte membranes and several mammalian tissues
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Introduction
Extracellular adenine nucleotides interact with cell surface P2-
purinoceptors in the central nervous system and peripheral
tissues to produce a broad range of physiological responses
(Dubyak & El-Moatassim, 1993). Classification of P2-pur-
inoceptors has proved difficult since no selective P2-receptor
antagonists are available. Nonetheless, observation of differ-
ential pharmacological effects of analogues of ATP led Burn-
stock & Kennedy (1985) to propose that at least two subtypes
of P2-purinoceptors exist. Pharmacological responses mediated
through P2x-purinoceptors, e.g. contraction of smooth muscle,
occurred with the potency order of a,fi-methyleneATP > ,y-
methyleneATP >ADP > 2-methylthioATP. Pharmacological
responses mediated through P2y-purinoceptors, e.g. relaxation
of smooth muscle, occurred with the potency order of 2-
methylthioATP >ATP> > cx,f-methyleneATP = fi,y-methyle-
neATP. P2-purinoceptors in addition to the P2x- and P2y-
subtypes exist (Dubyak & El-Moatassim, 1993; Fredholm et
al., 1994; Harden et al., 1995). The P27-purinoceptor is acti-
vated by ADP but not ATP and is expressed on platelets
(Haslam & Cusack, 1981; Hourani & Cusack, 1991). The P2U-
purinoceptor responds to ATP, UTP, and ATPyS, but only
weakly or not at all to other analogues ofATP including those
that are selective for P2x- and P2 -punoceptors (Dubyak et
al., 1988; Fine et al., 1989; Brown et al., 1991; Stutchfield &
Cockcroft, 1990). High concentrations of ATP permeabilize
cells through the so-called P2z-purinoceptor (Cockcroft &
Gomperts, 1980; Dubyak & El-Moatassim, 1993), but the
general physiological significance of this entity is not known.
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Evidence also exists for the need for subclassification within
the major P2-purinoceptor subtypes. For example, differences
in the relative potencies of a series of adenine nucleotide
analogues in several preparations led to the suggestion that
multiple P2X- and P2y-purinoceptors occur (Fischer et al., 1993;
Burnstock et al., 1994). cDNAs encoding two different P2X-
purinoceptors that exhibit different pharmacological selectiv-
ities have been cloned recently (Valera et al., 1994; Brake et al.,
1994). Studies with two model cell systems also suggest the
existence of multiple P2y-purinoceptor subtypes. The P2y-
purinoceptor on C6-2B rat glioma cells inhibits adenylyl cy-
clase, but has no effect on phospholipase C activity (Boyer et
al., 1993), whereas the P2y-purinoceptor on turkey erythrocyte
membranes activates phospholipase C but does not regulate
adenylyl cyclase (Boyer et al., 1989). These results are re-
miniscent of the G-protein/effector enzyme coupling selectiv-
ities in other receptor families. For example, MI, M3, and ms
muscarinic cholinoceptors activate phospholipase C, whereas
m2 and m4 muscarinic cholinoceptors inhibit adenylyl cyclase
(Hulme et al., 1990). The idea that the P2y-purinoceptor on C6
glioma cells differs from that on turkey erythrocytes also has
been supported by the fact that pyridoxal phosphate 6-azo-
phenyl 2',4'-disulphonic acid (PPADS) and reactive blue 2 are
markedly different in their effectiveness as antagonists in the
two model systems (Boyer et al., 1994).
Fischer et al. (1993) recently have reported the synthesis and
relative pharmacological activities of a set of analogues of
adenine nucleotides substituted on the purine ring as chain-
extended 2-thioethers. We have expanded our study of these
compounds to C6 rat glioma cells in which several analogues
ofATP displayed remarkable potency in the pM range for P2y-
purinoceptor activation. The relative potencies of a broad
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range of agonists at this adenylyl cyclase-coupled P2Y-pur-
inoceptor differed substantially from the relative potencies of
these agonists for activation of the phospholipase C-coupled
P2y-purinoceptor of turkey erythrocytes.
Methods
Cell culture
C6 rat glioma cells were grown in Dulbecco's Modified Eagle's
Medium (DMEM) supplemented with 5% foetal calf serum in
a humidified atmosphere of 95% air and 5% CO2. Cells were
passaged by trypsinization. Experiments were carried out in
confluent cultures 2-4 days after plating in 12-well clusters as
previously described (Boyer et al., 1993).
Cyclic AMP accumulation
Cells were labelled for 2 h with 1 uCi of [3H]-adenine ml-'
(Meeker & Harden, 1983). Cells were washed twice with
HEPES (20 mM, pH 7.5)-buffered Eagle's medium and then
preincubated for 10 min at 37°C with HEPES-Eagle's medium
containing 200 gM 3-isobutyl-1-methylxanthine. Agonist in-
cubations were initiated by the simultaneous addition of 10 /IM
isoprenaline and various concentrations of P2y-purinoceptor
agonists. The reactions were stopped after 10 min by aspira-
tion of the drug-containing medium and addition of 1 ml of
ice-cold 5% trichloroacetic acid. [3H]-cyclic AMP accumula-
tion was determined by Dowex and alumina chromatography
as previously described (Harden et al., 1982).
Turkey erythrocyte labelling
Fresh blood was obtained from female turkeys by venous
puncture and collected into a heparinized syringe. Ery-
throcytes were washed twice by centrifugation and resuspen-
sion with sterile DMEM, followed by a final wash in inositol-
free DMEM. One ml of washed packed erythrocytes was re-
suspended in a final volume of 4.2 ml of inositol-free DMEM
in the presence of 0.5 mCi [3H]-inositol. Cells were incubated
in a stirred glass vial for 16-20 h at 37°C in a humidified
atmosphere of 95% air, 5% CO2 as previously described in
detail (Harden et al., 1988; Boyer et al., 1989).
Phospholipase C assay
Erythrocyte ghost membranes were prepared from [3H]-inositol-
labelled cells by hypotonic lysis in 15 volumes of a buffer con-
taining 5 mm sodium phosphate, pH 7.4, 5 mM MgCl2 and
1 mM EGTA (Iysis buffer). The membranes were washed three
times by centrifugation and resuspension with lysis buffer. The
final resuspension was in 20 mM HEPES pH 7.0, to a con-
centration of 6 mg protein ml-'. This preparation was used
immediately for assay of phospholipase C. Twenty-five p1 of
[3H]-inositol-labelled membrane preparation (- 150 yg protein;
200,000 c.p.m.) was combined in a final volume of 200 y1 of a
medium containing 0.91 mM MgSO4, 115mM KCl, SmM po-
tassium phosphate, 0.424mM CaCl2, 2mM EGTA, 10mM
HEPES, pH 7.0 (free Ca"+ concentration wast 1 pM). Since
receptor- andG protein-activation ofphospholipase C in turkey
erythrocyte membranes is strictly dependent on the presence of
guanine nucleotides (Boyer et al., 1989), the non-hydrolyzable
analogue of GTP, GTPyS (1 pM), was included in the assay.
Membranes were incubated for 5 min at 30°C with the indicated
concentrations of P2y-purinoceptor agonists. Incubations were
terminated by the addition of 1 ml ofice cold 5% trichloroacetic
acid. Samples were centrifuged, the supernatants were trans-
ferred to a fresh tube, and the trichloroacetic acid was extracted
three times with 3 ml of ethyl ether. Neutralized samples of the
aqueous layer were diluted with 8 ml of water and transferred
onto Dowex AG-X8 columns (formate form). Columns were
washed with 8 ml of 200 mM ammonium formate, 100 mM
formic acid, and the eluant was discarded. Total inositol phos-
phates (IP2 through IP4) were eluted with 5 ml of 1.2 M ammo-
nium formate, 100 mM formic acid, and collected in scintillation
vials (Harden et al., 1988; Boyer et al., 1989). [3H]-inositol
phosphates were quantitated by scintillation spectroscopy.
Materials
2-Methylthio adenosine triphosphate (2-MeSATP) was ob-
tained from Research Biochemicals International. (Natick,
MA, U.S.A.); (-)-isoprenaline (+)-bitartrate and 8-(6-ami-
nohexylamino)ATP were from Sigma Chemical Co. (St. Louis,
MO, U.S.A.); 2-[3H]-myo-inositol (20 Ci mmol ') and [8-3H]-
adenine (27 Ci mmol-') were obtained from American Radi-
olabeled Chemicals, Inc. (St. Louis, MO, U.S.A.); inositol-free
DMEM was from Gibco BRL (Grand Island, NY, U.S.A.).
The sources of other materials have been reported previously
(Boyer et al., 1989; 1993; 1994).
Synthesis of 2-thioether analogues of ATP and ADP
A series of chain extended 2-thioether substituted analogues of
ATP and ADP were synthesized, purified and chemically
characterized as described previously (Fischer et al., 1993).
Data analysis
Agonist potencies were calculated using a four parameter lo-
gistic equation and the GraphPad software package (Graph-
Pad, San Diego, CA, U.S.A.). All concentration-effect curves
were repeated in at least three separate experiments using du-
plicate or triplicate assays.
Results
We have reported previously that ATP, ADP, and several
adenine nucleotide analogues inhibit isoprenaline-stimulated
cyclic AMP accumulation in C6-2B and C6 rat glioma cells
with a pharmacological specificity consistent with that of a
P2y-purinoceptor (Boyer et al., 1993). The parent C6 glioma
cell from which C6-2B cells were subcloned (de Vellis &
Brooker, 1973) also expresses P2y-purinoceptors as evidenced
by potent inhibition of cyclic AMP accumulation by the P2y-
purinoceptor agonist, 2-MeSATP (Boyer et al., 1994). The
maximal inhibition observed with 2-MeSATP was consistently
much greater (60-80% inhibition) than we previously ob-
served with C6-2B cells (Figure la and Boyer et al., 1993).
Pretreatment of cells with pertussis toxin completely blocked
the capacity of2-MeSATP to inhibit cyclic AMP accumulation
(Figure la), and a concentration-effect curve revealed that this
inhibition occurred at low concentrations of pertussis toxin
(Figure lb). Although 2-MeSATP was a very potent agonist
for inhibition of cyclic AMP accumulation, the P2-pur-
inoceptor agonists, a,fi-methyleneATP and fi,y-methyleneATP,
had little or no effect (Figure 2). As was the case with C6-2B
cells, ADP was approximately 50 fold more potent that ATP
for inhibition of cyclic AMP accumulation in C6 glioma cells.
The overall comparative potencies of the eight adenine nu-
cleotide analogues were consistent with the involvement of a
P2y-purinoceptor (Figure 2).
We earlier reported the synthesis of a series of 2-thioether
derivatives of ATP and ADP (Fischer et al., 1993). The ac-
tivities of these compounds were tested at the adenylyl cyclase-
linked P2y-purinoceptor on C6 glioma cells. Concentration
effect curves for 2-(5-hexenylthio)ATP, 2-(5-hexenylthio)ADP
and ATP are compared in Figure 3. The tri- and diphosphate
analogues exhibited remarkable potencies with EC50 values in
the 100 pM range. These analogue potencies represent 10,000
and 30,000 fold increases in potency over the parent ADP and
ATP congeners, respectively.
In light of the high potencies of the two hexenylthio ana-
logues, the effects on cyclic AMP accumulation of other 2-
2612













































0 1~ - I I __nI.........J..- I * a a
0 5 10lo 9 8 7 0 0.1 0.3 1 3 10
-log [2MeSATPJ (M) Pertussis toxin (ng mlF1)
Figure 1 Pertussis toxin-sensitive inhibition of isoprenaline-stimulated cyclic AMP accumulation by 2-MeSATP in C6 rat glioma
cells. (a) C6 cells were incubated overnight in the absence (0) or presence (0) of pertussis toxin (lOngml-P). The capacity of the
indicated concentrations of 2-MeSATP to inhibit isoprenaline-stimulated cyclic AMP accumulation was then determined. The data
are the mean + s.e.mean of three determinations. (b) C6 cells were incubated overnight with the indicated concentrations of pertussis
toxin. Isoprenaline (10/pM)-stimulated cyclic AMP accumulation then was quantitated in the absence (0) or presence (M) of
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FIgure 2 Inhibition of cyclic AMP accumulation by adenine
nucleotide analogues. The capacity of the indicated concentrations
of 2-MeSATP (0), ADPfS (0), 2-ClATP (*), ADP (0), ATPyS
(-), ATP (A), fl,yMeATP (U), and a,fiMeATP (E) to inhibit
isoprenaline-stimulated cyclic AMP accumulation was determined as
described in Methods. Data shown are the mean of triplicate
determinations and the results are representative of those obtained
in three separate experiments.
thioether-substituted adenine nucleotide analogues were de-
termined. The most potent agonists were 2-cyclohexylthio-
ATP and 2-hexylthioATP, which both exhibited EC50 values of
approximately 30 pM. Thus, 2-thioether substitution of a
number of analogues resulted in an increase in potency of
greater than 5 orders of magnitude relative to that of ATP
(Table 1 and Figure 3). However, 2-(7-aminoheptylthio)ATP,
which was the least potent of the eight 2-thioether derivatives
of ATP that were tested, was approximately as potent as ATP
itself. Although only a single diphosphate analogue was tested
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Figure 3 Inhibition of cyclic AMP accumulation by chain-extended
2-thioether derivatives of ATP and ADP. The capacity of the
indicated concentrations of 2-(5-hexenylthio)ATP (-), 2-(5-hexe-
nylthio)ADP (0), and ATP (C) to inhibit isoprenaline-stimulated
cyclic AMP accumulation was determined as described in Methods.
Data shown are the mean of triplicate determinations and the results
are representative of those obtained in three separate experiments.
as the corresponding triphosphate. This near equipotency was
shown to hold for other di- and triphosphate pairs in other
P2y-purinoceptor test systems (Fischer et al., 1993).
We have reported earlier that N6-substitution of adenine
nucleotides results in a loss of potency of these compounds at
P2x-purinoceptors with little change occurring in relative po-
tency for P2y-purinoceptors (Fischer et al., 1993). One such
compound, N6-methyl-2-(5-hexenylthio)ATP, was tested and
shown to retain its high potency at the C6 cell P2y-pur-
inoceptor, although the corresponding analogue lacking the
N6-methyl group was 3 fold more potent (Table 1). N6-me-
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Table 1 Selectivity of adenine nucleotide analogues for activation of P2y-purinoceptor-regulated responses in turkey erythrocyte
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EC50 values were determined as described in Methods. Except where indicated all values are the mean± s.e.mean of values from at least
three different determinations. * Partial inhibition at 100 iim; **n = 1; ***taken from Fischer et al. (1993).
thyIATP had little or no inhibitory effect on cyclic AMP ac-
cumulation in C6 cells, which contrasts with the inhibitory
effect observed with ATP alone. Since we have shown pre-
viously that N6-substituted analogues ofATP are not active at
P2x-purinoceptors (Fischer et al., 1993), N6-methyl-2-(5-hex-
enylthio)ATP represents a very high potency P2y-pur-
inoceptor-selective agonist.
The P2y-purinoceptor on C6 glioma cells is different from
that on turkey erythrocytes, based on both the specificity of
second messenger coupling of these receptors to signalling re-
sponses (Boyer et al., 1989; 1993) and the relative selectivity of
antagonism by two purinoceptor antagonists (Boyer et al.,
1994). The data with 2-thioether derivatives of adenine nu-
cleotides also were consistent with the involvement of two
different receptors in the two test systems (Table 1 and Figure
4). Thus, some agonists exhibited similar potencies in the two
model systems, e.g. 2-ClATP and ADPfS, some agonists were
much more potent at the C6 cell receptor than at the turkey
erythrocyte receptor, e.g. 2-cyclohexylthioATP and 2-hex-
ylthioATP, and several agonists were less potent in the C6 than
in the turkey erythrocyte system, e.g. 2-(7-amino-
heptylthio)ATP, 3'NH2-ATP, N6-methylATP, and 8-(6-ami-
nohexylamino)ATP.
The presence of a long-chain thioether at the 2-position of
adenosine di- and triphosphates increased potency in both
functional receptor subtypes. However, this structural feature
resulted in increased selectivity of triphosphate analogues for
the adenylyl cyclase linked receptor. The degree of selectivity
depended very much on the structure of the thioether sub-
stitutent. A small alkyl group, e.g. 2-MeSATP, provided only
8.1 fold selectivity. Larger alkyl thioethers, such as hexenyl and
hexyl, resulted in selectivity for the C6 cell P2y-receptor of
roughly 100 fold. Curiously, the presence of a cyano functional
group at the distal position of hexyl alkyl chain reduced the
degree of selectivity from 170 to 3.2 fold, entirely as a result of
the change in potency in C6 cells. A nitrophenylethyl thioether
also diplayed only moderate selectivity for C6 cell receptors.
The enhancement of selectivity for the adenylyl cyclase-linked
receptor associated with the presence of a long chain 2-thioe-
ther was not observed for the 2-Cl analogue or for modifica-
tion of ATP at other sites, e.g. N6, 3', or on the triphosphate
group (Table 1). The N6-methyl substitution did not preclude
the appearance of selectivity for the adenylyl cyclase-linked
receptor, since N6-methyl-2-(5-hexenylthio)ATP was 81 fold
selective. ADP was 120 fold selective for the adenylyl cyclase
linked receptor, and approximately the same degree of se-
lectivity was observed for a long chain (hexyl) thioether of
ADP.
Discussion
Pianet and coworkers (1989) first reported that ADP and ATP
inhibited cyclic AMP accumulation in C6 rat glioma cells,
which was subsequently confirmed by others (Valeins et al.,
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Figue 4 Comparison of the relative potencies of adenine nucleotide
analogues for stimulation of two different P2y-purinoceptor-regulated
responses. Concentration-effect curves for 20 compounds were
generated for the adenylyl cyclase-linked P2y-purinoceptor of C6
glioma cells and the phospholipase C-linked P2y-purinoceptor of
turkey erythrocytes. The average pK0.5 for at least three different
experiments in each case is plotted for the turkey erythrocyte
response (abscissa scale) and C6 cell response (ordinate scale).
Numbers in the plot correspond to nucleotides as indicated in Table
1. pKio.5 values for 3'-NH2ATP and N6-MeATP (nucleotides 11 and
12, respectively) on C6 cells are approximate, since only a partial
effect was observed at 1001iM. Compounds 7 and 18 are super-
imposed in the plot.
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data (Boyer et al., 1993) and data presented here illustrate that
this inhibitory effect of adenine nucleotides is mediated
through a P2y-purinoceptor. Analogues of adenine nucleotides
modified on the purine ring as chain-extended 2-thioethers
exhibited remarkable potencies for the adenylyl cyclase-cou-
pled P2r-purinoceptor of C6 glioma cells. Several of these 2-
thioether derivatives exhibited potencies at C6 cell P2Y-pur-
inoceptors that were at least 30 fold greater than that of 2-
MeSATP, which was the initially useful compound for phar-
macologically delineating P2y-purinoceptors. Compared to the
potency of ATP, some of these agonists represent increases in
potencies of at least 5 orders of magnitude. 2(5-Hexenylthio)
ADP, the single ADP analogue that was tested, also exhibited
a potency that was 3 orders of magnitude more potent than
ADP itself. The fact that ADP and its analogues are at least as
potent as ATP and the corresponding triphosphate analogues
suggests that analogues ofADP might be preferable to those of
ATP as P2y-purinoceptor agonists. That is, ADP analogues are
much less likely to interact with P2x- (Fischer et al., 1993;
Burnstock et al., 1994; Valera et al., 1994) or P2U-pur-
inoceptors (Dubyak et al., 1988; Fine et al., 1989; Brown et al.,
1991; Lustig et al., 1993) or with ATP-binding enzymes.
The cyclic AMP-regulating P2Y-purinoceptor on C6 glioma
cells apparently represents a different receptor type from the
P2Y-purinoceptor on turkey erythrocytes. No evidence for
coupling of the C6 cell receptor to phospholipase C has been
observed even though this effector system is present in the cells,
and stimulation of the erythrocyte receptor results in activa-
tion of phospholipase C with no effects on adenylyl cyclase.
These results have been corroborated with data from the
cloned turkey P2y-purinoceptor heterologously expressed in
1321N1 human astrocytoma cells (Filtz et al., 1994) and after
expression of the human homologue of this receptor (J.L.
Schachter, Q. Li, R.A. Nicholas & T.L. Harden, unpublished
observations). The expressed receptor promoted inositol lipid
hydrolysis without producing any effects on cyclic AMP levels.
The idea that different P2y-purinoceptors couple to different
second messenger pathways was also supported by differential
effects of two antagonists of P2-purinoceptors in the two model
test systems (Boyer et al., 1994). Although the delineation of
multiple subtypes within a receptor class are often difficult to
make by use of receptor agonists alone, the data presented here
comparing relative agonist affinities between the two P2Y-
purinoceptor-regulated second messenger systems add further
support to the notion that these are pharmacologically distinct
P2Y-purinoceptor subtypes. For example, a number of the
chain-extended 2-thioether derivatives of ATP were much
more potent activators of the C6 cell than of the turkey ery-
throcyte purinoceptor. In contrast N6-methylATP was essen-
tially inactive at the C6 cell P2y-purinoceptor, but was
equipotent with ATP at the P2y-purinoceptor of turkey ery-
throcytes and of several mammalian smooth muscle prepara-
tions (Fischer et al., 1993). Although the agonist potencies at
the C6 cell P2Y-purinoceptor only have been compared to
potencies at turkey erythrocytes these differences also will hold
for mammalian P2y-purinoceptors. That is, we have reported
previously that the potencies of agonists at the turkey ery-
throcyte receptor are closely aligned with those for the same
agonists at the guinea-pig taenia coli (Fischer et al., 1993).
Perhaps the most remarkable observation made in this
study is that agonists can be synthesized that activate P2y-
purinoceptors in the pM range of concentrations. The potential
contribution of receptor reserve to this very high potency of
agonists has not been examined. The fact that so many of the
chain-extended 2-thioether derivatives were more potent at C6
cells than in erythrocyte membranes is suggestive that con-
siderable receptor reserve may exist for these adenylyl cyclase-
regulating receptors. However, the similar potencies between
the two systems observed with the classically used P2y-pur-
inoceptor agonists, 2-ClATP and ADPfiS, and of ATP itself,
make this argument less tenable. An alternate explanation is
that the differences reflect differences in conformation or in
crucial amino acids in the receptor binding site responsible for
ligand recognition. The potential existence of receptor reserve
in the C6 cells also does not fit with the observation that cer-
tain agonists, e.g. 2-(7-aminoheptylthio)ATP and 3'-NH2-
ATP, were more potent activators of the turkey erythrocyte
than the C6 cell receptor. Means of irreversibly inactivating or
down-regulating the C6 cell P2y-purinoceptor will need to be
delineated to address this issue adequately.
In summary, C6 glioma cells provide an excellent model for
the study of an adenylyl cyclase-linked P2y-purinoceptor. As-
suming that receptor reserve is not a major contributor, the
remarkably high potencies observed with adenine nucleotide
analogues at C6 cell P2y-purinoceptors represent some of the
largest substitution-promoted increases in potencies over that
of a natural receptor agonist of which we are aware. The
possibility of obtaining agonist potencies in the pM range raises
a number of possibilities. For example, we now have identified
substitutions that may allow us to synthesize P2-purinoceptor
agonists that are not nucleotides.
The authors are indebted to Brenda K. Lindsey for excellent help in
preparing the manuscript and to Teresa Romero for technical
assistance. This work was supported by USPHS grants GM38213,
GM29536, and HL32322.
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